RS55466B1 - Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3 - Google Patents

Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3

Info

Publication number
RS55466B1
RS55466B1 RS20161120A RSP20161120A RS55466B1 RS 55466 B1 RS55466 B1 RS 55466B1 RS 20161120 A RS20161120 A RS 20161120A RS P20161120 A RSP20161120 A RS P20161120A RS 55466 B1 RS55466 B1 RS 55466B1
Authority
RS
Serbia
Prior art keywords
aliphatic residue
residue
unsubstituted
polysubstituted
mono
Prior art date
Application number
RS20161120A
Other languages
English (en)
Serbian (sr)
Inventor
Simon Lucas
Sven Kühnert
Gregor Bahrenberg
Wolfgang Schröder
Achim Kless
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of RS55466B1 publication Critical patent/RS55466B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
RS20161120A 2012-04-18 2013-04-17 Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3 RS55466B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12002709 2012-04-18
EP13719386.8A EP2888233B1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
PCT/EP2013/001134 WO2013156154A1 (en) 2012-04-18 2013-04-17 Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators

Publications (1)

Publication Number Publication Date
RS55466B1 true RS55466B1 (sr) 2017-04-28

Family

ID=48227140

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20161120A RS55466B1 (sr) 2012-04-18 2013-04-17 Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3

Country Status (21)

Country Link
EP (1) EP2888233B1 (https=)
JP (1) JP6033403B2 (https=)
CN (1) CN104428287A (https=)
AR (1) AR090739A1 (https=)
AU (1) AU2013248637A1 (https=)
BR (1) BR112014025840A2 (https=)
CA (1) CA2870573A1 (https=)
CY (1) CY1118255T1 (https=)
DK (1) DK2888233T3 (https=)
EA (1) EA201401142A1 (https=)
ES (1) ES2605947T3 (https=)
HK (1) HK1210173A1 (https=)
HR (1) HRP20161424T1 (https=)
HU (1) HUE030859T2 (https=)
IL (1) IL235030A0 (https=)
LT (1) LT2888233T (https=)
MX (1) MX2014012494A (https=)
PT (1) PT2888233T (https=)
RS (1) RS55466B1 (https=)
SI (1) SI2888233T1 (https=)
WO (1) WO2013156154A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201809184VA (en) * 2016-04-22 2018-11-29 Ono Pharmaceutical Co Crystal polymorphism of kcnq2-5 channel activator
JP7262468B2 (ja) * 2017-12-29 2023-04-21 スリーエム イノベイティブ プロパティズ カンパニー 熱硬化性2剤型加工用接着剤組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2230392A1 (de) 1972-06-22 1974-01-31 Cassella Farbwerke Mainkur Ag Substituierte pyridinverbindungen und verfahren zu ihrer herstellung
DE2513949A1 (de) 1975-03-29 1976-10-07 Bayer Ag Azofarbstoffe
CA2438868A1 (en) 2001-02-20 2002-09-19 Valentin K. Gribkoff Modulators of kcnq potassium channels and use thereof in treating migraine and mechanistically related diseases
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
HRP20120822T1 (hr) 2008-10-24 2012-11-30 Grünenthal GmbH Supstituirani 4,5,6,7-tetrahidrotienopiridini kao kcnq2/3 modulatori za lijeäśenje boli, epilepsije i urinarne inkontinencije
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
PE20140199A1 (es) * 2010-10-20 2014-02-16 Gruenenthal Chemie 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3

Also Published As

Publication number Publication date
ES2605947T3 (es) 2017-03-17
EP2888233A1 (en) 2015-07-01
DK2888233T3 (en) 2017-01-09
HUE030859T2 (en) 2017-06-28
MX2014012494A (es) 2015-01-15
JP6033403B2 (ja) 2016-11-30
SI2888233T1 (sl) 2016-12-30
CY1118255T1 (el) 2017-06-28
CA2870573A1 (en) 2013-10-24
BR112014025840A2 (pt) 2017-07-18
EA201401142A1 (ru) 2015-03-31
LT2888233T (lt) 2017-01-10
EP2888233B1 (en) 2016-09-28
CN104428287A (zh) 2015-03-18
PT2888233T (pt) 2017-01-04
JP2015514728A (ja) 2015-05-21
AU2013248637A1 (en) 2014-12-04
HK1210173A1 (en) 2016-04-15
WO2013156154A1 (en) 2013-10-24
HRP20161424T1 (hr) 2016-12-16
IL235030A0 (en) 2014-12-31
AR090739A1 (es) 2014-12-03

Similar Documents

Publication Publication Date Title
NZ595759A (en) Substituted phenylureas and phenylamides as vanilloid receptor ligands
MX338887B (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble.
WO2015028966A3 (en) Amino diacids containing peptide modifiers
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PE20120307A1 (es) Derivados de indazol como antagonistas del receptor ccr4
EP3699176A3 (en) Antiviral compounds
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
PE20140630A1 (es) Derivados de acido 3-fenilpropionico ramificados y su uso
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
HRP20210526T1 (hr) Oksisteroli i postupci za njihovu uporabu
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
PH12013500301A1 (en) Oxadiazole inhibitors of leukotriene production
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
FI3572405T3 (fi) Benzoimidatsol-1,2-yyli amidit kv7 kanavan aktivaattoreina
NZ701933A (en) Phenoxyethyl piperidine compounds
PE20161369A1 (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona sustituidos con tetrazolona
RS55466B1 (sr) Supstituisani 6-amino-nikotinamidi koji imaju grupu koja sadrži oh kao modulatori kcnq2/3
PL417980A1 (pl) Nowe fosfotriazolowe analogi kapu końca 5' mRNA, kompozycja je zawierająca, cząsteczka RNA je zawierająca, ich zastosowania i sposób syntezy cząsteczki RNA, białka i peptydu
HRP20150526T1 (hr) Supstituirani 2-oksi-kinolin-3-karboksamidi kao modulatori kcnq2/3
GB201018519D0 (en) Novel treatment of multiple sclerosis (MS)
JP2016531846A5 (https=)
IN2013DN02555A (https=)